Skip to content
DataLookout
Menu

NCT06249048

Phase 1/2 Study of Intratumoral Injection of STX-001 in Advanced Solid Tumors as Monotherapy or in Combination With Pembrolizumab

StatusCompleted
PhasePhase 1/2
Primary completion
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 10 versions: 9 with changes below, 1 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Notable Eligibility criteria expanded, about 49 words Show 6 more changesShow less
    • Primary endpoints: details revised at 1 of 2 entries
    • Trial completed
    • Final enrollment: 39 participants (planned 108)
    • Primary completion date changed from estimate of May 2027 to Jun 17, 2026
    • Secondary endpoints: details revised at 3 of 9 entries
    • Site details revised at 7 of 7 sites
  2. Notable Eligibility criteria revised
    • Study sites: 4 to 7
    • Study description expanded, about 37 words
    • Study arms: 3 to 5
    v9
  3. Minor Secondary endpoints: 8 to 9v7
  4. Notable Eligibility criteria shortened, about 1 wordv6
  5. Notable Eligibility criteria expanded, about 141 wordsv5 Show 4 more changesShow less
    • Primary endpoints revised (2)
    • Secondary endpoints: 14 to 8
    • Study description shortened, about 1 word
    • Study title expanded, about 2 words
Show 3 earlier versionsHide 3 earlier versions
  1. Minor Site details revised at 3 of 4 sitesv4
  2. Notable Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 5 to 4
    • Start date changed from estimate of Apr 2024 to May 3, 2024
    v3
  3. Notable Primary endpoints revised (2)
    • Secondary endpoints: 9 to 14
    • Study title shortened, about 2 words
    v2
  1. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Number and nature of dose-limiting toxicities (DLTs), treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs) in patients with advanced solid tumors.
Timeframe: From time of informed consent until 30 days after the last dose of investigational product (STX-001).
Occurrence of changes from baseline in patients' clinical safety laboratory values and vital signs to assess the safety and tolerability of STX-001.
Timeframe: From time of informed consent until 30 days after the last dose of investigational product (STX-001).

Secondary (7)

Assessment of PK in patients dosed with STX-001
Assessment of Tumor infiltrating lymphocytes (TILs)
Number and nature of preliminary antitumor activity of STX-001.
Number and nature of preliminary antitumor activity of STX-001 in combination with pembrolizumab.
Occurrence of TEAEs, SAEs, and AESIs graded according to NCI CTCAE v5.0
Show 2 moreShow less
Occurrence of changes from baseline in patients' clinical safety laboratory values and vital signs to assess the safety and tolerability of STX-001.in combination with pembrolizumab.
Objective Response Rate (ORR) in patients with advanced solid tumors.

Arms and interventions

Phase 1 Monotherapy (STX-001)Experimental

A Phase 1, first-in-human (FIH), multiple ascending dose administration of intratumoral STX-001 monotherapy to evaluate safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and preliminary antitumor activity in patients with advanced cancers. Consists of four planned dose-escalation cohorts (Cohorts 1m) plus permitted backfill enrollment (up to 30 patients). New patients are enrolled in each dose escalation cohort, and dose escalation may be stopped early if emerging PK or safety data warrant it. Dose extension and treatment pauses are integrated, with a maximum extension of 35 cycles (≈24 months).

Phase 1 Combination (STX-001 with Pembrolizumab)Experimental

A Phase 1, first-in-human (FIH), multiple ascending STX-001 dose administration, in combination with pembrolizumab, to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary antitumor activity in patients with advanced cancers. Consists of 4 planned dose escalation cohorts (Cohorts 1c) of STX-001and pembrolizumab given concurrently, with new patients enrolled in each dose escalation cohort. Dose escalation may be halted early if PK or safety data indicate, and the dose extension period extends up to 35 cycles with treatment pauses. Backfill enrollment is permitted up to 30 patients.

Phase 2 Combination (STX-001 with Pembrolizumab)Experimental

Phase 2 consists of dose expansion cohorts in patients with 2 defined cancer types: triple negative breast cancer (TNBC) and melanoma. Phase 2 will evaluate STX-001 in combination with pembrolizumab; the recommended Phase 2 dose (RP2D) of STX-001 will be selected based on analysis of the totality of data from Phase 1 safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and preliminary efficacy data. Dose extension and treatment pauses are incorporated.

Phase 1 Visceral-lesion Monotherapy (Cohort 1Vm)Experimental

Phase 1, first-in-human (FIH) monotherapy cohort targeting visceral lesions. STX-001 is administered intratumorally at 30 µg, 100 µg and 300 µg to evaluate safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary antitumor activity in patients with advanced cancers. Cohort 1Vm is part of the dose escalation stage; new patients are enrolled at each dose level, and backfill enrollment is permitted up to 30 patients. Dose escalation may be stopped early if PK or safety data warrant it.

Phase 2 Advanced-Melanoma MonotherapyExperimental

Phase 2 dose expansion cohort evaluating STX-001 monotherapy administered intratumorally to patients with advanced melanoma. Assesses safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary antitumor activity with the recommended dose selected based on Phase 1 data. Dose extension and treatment pauses are allowed up to 35 cycles.

Biologicals: STX-001, Keytruda®

Sites

7 sites in 2 countries

United States 6, Australia 1